Literature DB >> 1846552

Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.

J M Cunningham1, G E Francis, M J Holland, K F Pirollo, E H Chang.   

Abstract

Inherited susceptibility to a wide variety of neoplasias (Li-Fraumeni syndrome), has been shown in studies of one cancer-prone family, to have an intriguing association with an aberrant c-raf-1 gene and inheritance of a radioresistant phenotype in their non-cancerous skin fibroblasts. This association together with observations that DNA topoisomerases, when defective, can introduce errors into DNA and that these enzymes are perturbed in vitro by serine/threonine kinases similar to raf encoded proteins, prompted investigation of DNA topoisomerase activity of the family's fibroblasts. Since radioresistance was transferred to murine cells (NIH-3T3) when the aberrant c-raf-1 gene from this family was transfected, we also examined transformants containing this and other oncogenes. V-raf/c-myc and EJ-ras transformants were examined, the former because the family's skin fibroblasts also have 3-8-fold elevated myc expression (not apparently relevant to radioresistance) and the latter because ras, like raf, conveys radioresistance. The family members' fibroblasts and the three transfected murine lines, showed a similar perturbation of a spermidine and ATP-dependent DNA catenation activity (typical of DNA topoisomerase II). There was a significant positive correlation (r = 0.93; P = 0.0026) between the degree of activation of topoisomerase II and one measure of radioresistance (the Dq value). Relaxation of DNA supercoiling (topoisomerase I activity and other DNA nicking enzymes) was not abnormal. Cytotoxicity assays and evaluation of the influence of topoisomerase II inhibitors on DNA/protein complex formation, corroborated the existence of a qualitative topoisomerase II defect in the family's cells and transfectants. Although the contention that the qualitative topoisomerase II abnormalities observed here may be associated with malfunction is highly speculative, these findings may be relevant to the mechanism of oncogenesis, not only in this family, but with raf and ras type oncogenes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846552      PMCID: PMC1971654          DOI: 10.1038/bjc.1991.8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  50 in total

1.  Is DNA topoisomerase involved in the UV excision repair process? New evidence from studies with DNA intercalating and non-intercalating antitumor agents.

Authors:  R D Snyder
Journal:  Photochem Photobiol       Date:  1987-01       Impact factor: 3.421

2.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

3.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

4.  Catenation of DNA rings by topoisomerases. Mechanism of control by spermidine.

Authors:  M A Krasnow; N R Cozzarelli
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

5.  Phosphorylation of purified Novikoff hepatoma topoisomerase I.

Authors:  E Durban; J S Mills; D Roll; H Busch
Journal:  Biochem Biophys Res Commun       Date:  1983-03-29       Impact factor: 3.575

6.  A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells.

Authors:  G J Finlay; B C Baguley; W R Wilson
Journal:  Anal Biochem       Date:  1984-06       Impact factor: 3.365

7.  Normal cytotoxic response of skin fibroblasts from patients with Li-Fraumeni familial cancer syndrome to DNA-damaging agents in vitro.

Authors:  J B Little; J Nove; W K Dahlberg; P Troilo; W W Nichols; L C Strong
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

8.  Genealogy of cancer in a family.

Authors:  W A Blattner; D B McGuire; J J Mulvihill; B C Lampkin; J Hananian; J F Fraumeni
Journal:  JAMA       Date:  1979-01-19       Impact factor: 56.272

9.  In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants.

Authors:  D N Carney; J B Mitchell; T J Kinsella
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  Mutations in the gene coding for Escherichia coli DNA topoisomerase I affect transcription and transposition.

Authors:  R Sternglanz; S DiNardo; K A Voelkel; Y Nishimura; Y Hirota; K Becherer; L Zumstein; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

View more
  4 in total

Review 1.  Topoisomerase expression in cancer cell lines and clinical samples.

Authors:  L A Doyle
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  p53 mutations increase resistance to ionizing radiation.

Authors:  J M Lee; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

3.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

4.  Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome.

Authors:  R Mirzayans; R A Aubin; W Bosnich; W A Blattner; M C Paterson
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.